SE9502219D0 - Novel medical use - Google Patents

Novel medical use

Info

Publication number
SE9502219D0
SE9502219D0 SE9502219A SE9502219A SE9502219D0 SE 9502219 D0 SE9502219 D0 SE 9502219D0 SE 9502219 A SE9502219 A SE 9502219A SE 9502219 A SE9502219 A SE 9502219A SE 9502219 D0 SE9502219 D0 SE 9502219D0
Authority
SE
Sweden
Prior art keywords
pct
medical use
novel medical
sec
date
Prior art date
Application number
SE9502219A
Other languages
English (en)
Swedish (sv)
Inventor
Lars Faendriks
Anders Pettersson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9502219A priority Critical patent/SE9502219D0/xx
Publication of SE9502219D0 publication Critical patent/SE9502219D0/xx
Priority to ZA964690A priority patent/ZA964690B/xx
Priority to EE9700366A priority patent/EE03385B1/xx
Priority to IL12265996A priority patent/IL122659A/xx
Priority to SK1721-97A priority patent/SK172197A3/sk
Priority to RU98101105/14A priority patent/RU2209064C2/ru
Priority to CA002225175A priority patent/CA2225175A1/en
Priority to CN96196137A priority patent/CN1091595C/zh
Priority to DK96918965T priority patent/DK0840607T3/da
Priority to AT96918965T priority patent/ATE214925T1/de
Priority to AU11840/97A priority patent/AU706660B2/en
Priority to PCT/SE1996/000758 priority patent/WO1997000070A1/en
Priority to NZ310606A priority patent/NZ310606A/en
Priority to US08/702,522 priority patent/US6096772A/en
Priority to HU9901448A priority patent/HUP9901448A3/hu
Priority to BR9608472A priority patent/BR9608472A/pt
Priority to DE69620186T priority patent/DE69620186T2/de
Priority to EP96918965A priority patent/EP0840607B1/en
Priority to PT96918965T priority patent/PT840607E/pt
Priority to ES96918965T priority patent/ES2173294T3/es
Priority to JP9502982A priority patent/JPH11507921A/ja
Priority to HK98111234.6A priority patent/HK1010152B/en
Priority to CZ19973730A priority patent/CZ289400B6/cs
Priority to KR1019970709491A priority patent/KR19990023021A/ko
Priority to MYPI96002480A priority patent/MY114716A/en
Priority to UA97126085A priority patent/UA55387C2/uk
Priority to IS4619A priority patent/IS4619A/is
Priority to MXPA/A/1997/010002A priority patent/MXPA97010002A/xx
Priority to NO975922A priority patent/NO975922L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
SE9502219A 1995-06-19 1995-06-19 Novel medical use SE9502219D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9502219A SE9502219D0 (sv) 1995-06-19 1995-06-19 Novel medical use
ZA964690A ZA964690B (en) 1995-06-19 1996-06-05 Novel medical use
KR1019970709491A KR19990023021A (ko) 1995-06-19 1996-06-10 신규한 의약 용도
NZ310606A NZ310606A (en) 1995-06-19 1996-06-10 Use of angiotensin II type 1 receptor antagonists for the treatment of dyspeptic symptoms
BR9608472A BR9608472A (pt) 1995-06-19 1996-06-10 Uso de um composto preparação farmacêutica e processo para uso na profilaxa e/ou tratamento de sintomas dispépticos
SK1721-97A SK172197A3 (en) 1995-06-19 1996-06-10 Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same
RU98101105/14A RU2209064C2 (ru) 1995-06-19 1996-06-10 Новое применение в медицинских целях
CA002225175A CA2225175A1 (en) 1995-06-19 1996-06-10 Novel medical use
CN96196137A CN1091595C (zh) 1995-06-19 1996-06-10 一种化合物在制备治疗消化不良症药物中的用途
DK96918965T DK0840607T3 (da) 1995-06-19 1996-06-10 Ny medicinsk anvendelse
AT96918965T ATE214925T1 (de) 1995-06-19 1996-06-10 Neue medizinische verwendung
AU11840/97A AU706660B2 (en) 1995-06-19 1996-06-10 Use of certain angiotensin II type I receptor antagonists for dyspeptic symptons in mammals including man
PCT/SE1996/000758 WO1997000070A1 (en) 1995-06-19 1996-06-10 Novel medical use
EE9700366A EE03385B1 (et) 1995-06-19 1996-06-10 Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
US08/702,522 US6096772A (en) 1995-06-19 1996-06-10 Use of Angiotensin II type 1 receptor antagonists in the treatment of dyspeptic symptoms
HU9901448A HUP9901448A3 (en) 1995-06-19 1996-06-10 Novel medical use
IL12265996A IL122659A (en) 1995-06-19 1996-06-10 Pharmaceutical compositions for the treatment of dyspeptic symptoms comprising angiotensin ii type receptor antagonists
DE69620186T DE69620186T2 (de) 1995-06-19 1996-06-10 Neue medizinische verwendung
EP96918965A EP0840607B1 (en) 1995-06-19 1996-06-10 Novel medical use
PT96918965T PT840607E (pt) 1995-06-19 1996-06-10 Nova utilizacao medica
ES96918965T ES2173294T3 (es) 1995-06-19 1996-06-10 Nuevo uso medico.
JP9502982A JPH11507921A (ja) 1995-06-19 1996-06-10 新規な医薬用途
HK98111234.6A HK1010152B (en) 1995-06-19 1996-06-10 Novel medical use
CZ19973730A CZ289400B6 (cs) 1995-06-19 1996-06-10 Léčivo pro léčení dyspeptických symptomů
MYPI96002480A MY114716A (en) 1995-06-19 1996-06-19 Prophylactic and/or therapeutic treatment of dyspeptic symptoms
UA97126085A UA55387C2 (uk) 1995-06-19 1996-10-06 Антагоністи ангіотензин-іі-рецептора типу 1 як активного інгредієнта медикаменту, ефективного для профілактики і лікування диспепсії, фармацевтична композиція та спосіб профілактики та лікування диспепсії
IS4619A IS4619A (is) 1995-06-19 1997-11-25 Ný læknisfræðileg notkun
MXPA/A/1997/010002A MXPA97010002A (es) 1995-06-19 1997-12-10 Nuevo uso medico
NO975922A NO975922L (no) 1995-06-19 1997-12-16 Ny medisinsk anvendelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9502219A SE9502219D0 (sv) 1995-06-19 1995-06-19 Novel medical use

Publications (1)

Publication Number Publication Date
SE9502219D0 true SE9502219D0 (sv) 1995-06-19

Family

ID=20398663

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9502219A SE9502219D0 (sv) 1995-06-19 1995-06-19 Novel medical use

Country Status (27)

Country Link
US (1) US6096772A (cs)
EP (1) EP0840607B1 (cs)
JP (1) JPH11507921A (cs)
KR (1) KR19990023021A (cs)
CN (1) CN1091595C (cs)
AT (1) ATE214925T1 (cs)
AU (1) AU706660B2 (cs)
BR (1) BR9608472A (cs)
CA (1) CA2225175A1 (cs)
CZ (1) CZ289400B6 (cs)
DE (1) DE69620186T2 (cs)
DK (1) DK0840607T3 (cs)
EE (1) EE03385B1 (cs)
ES (1) ES2173294T3 (cs)
HU (1) HUP9901448A3 (cs)
IL (1) IL122659A (cs)
IS (1) IS4619A (cs)
MY (1) MY114716A (cs)
NO (1) NO975922L (cs)
NZ (1) NZ310606A (cs)
PT (1) PT840607E (cs)
RU (1) RU2209064C2 (cs)
SE (1) SE9502219D0 (cs)
SK (1) SK172197A3 (cs)
UA (1) UA55387C2 (cs)
WO (1) WO1997000070A1 (cs)
ZA (1) ZA964690B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6602248B1 (en) 1995-06-07 2003-08-05 Arthro Care Corp. Methods for repairing damaged intervertebral discs
US20050004634A1 (en) 1995-06-07 2005-01-06 Arthrocare Corporation Methods for electrosurgical treatment of spinal tissue
WO2003024506A2 (en) 2001-09-14 2003-03-27 Arthrocare Corporation Methods and apparatus for treating intervertebral discs
US7393351B2 (en) 1995-06-07 2008-07-01 Arthrocare Corporation Apparatus and methods for treating cervical inter-vertebral discs
US6726684B1 (en) 1996-07-16 2004-04-27 Arthrocare Corporation Methods for electrosurgical spine surgery
US6620155B2 (en) 1996-07-16 2003-09-16 Arthrocare Corp. System and methods for electrosurgical tissue contraction within the spine
US7357798B2 (en) 1996-07-16 2008-04-15 Arthrocare Corporation Systems and methods for electrosurgical prevention of disc herniations
SE9800550D0 (sv) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
US20030158545A1 (en) 2000-09-28 2003-08-21 Arthrocare Corporation Methods and apparatus for treating back pain
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
CA2464561A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
ATE487478T1 (de) * 2003-01-30 2010-11-15 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US8979838B2 (en) 2010-05-24 2015-03-17 Arthrocare Corporation Symmetric switching electrode method and related system
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2263635A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
GB2263637A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
GB2263638A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Also Published As

Publication number Publication date
DK0840607T3 (da) 2002-05-06
ZA964690B (en) 1996-12-19
CN1091595C (zh) 2002-10-02
CN1192681A (zh) 1998-09-09
AU1184097A (en) 1997-01-15
UA55387C2 (uk) 2003-04-15
AU706660B2 (en) 1999-06-17
ATE214925T1 (de) 2002-04-15
NO975922D0 (no) 1997-12-16
EE9700366A (et) 1998-06-15
JPH11507921A (ja) 1999-07-13
KR19990023021A (ko) 1999-03-25
US6096772A (en) 2000-08-01
HUP9901448A2 (hu) 2000-04-28
IS4619A (is) 1997-11-25
MX9710002A (es) 1998-07-31
ES2173294T3 (es) 2002-10-16
WO1997000070A1 (en) 1997-01-03
CZ289400B6 (cs) 2002-01-16
SK172197A3 (en) 1998-07-08
EP0840607B1 (en) 2002-03-27
RU2209064C2 (ru) 2003-07-27
MY114716A (en) 2002-12-31
CZ373097A3 (cs) 1998-05-13
PT840607E (pt) 2002-09-30
EE03385B1 (et) 2001-04-16
HK1010152A1 (en) 1999-06-17
NZ310606A (en) 2001-03-30
IL122659A (en) 2003-01-12
NO975922L (no) 1997-12-16
BR9608472A (pt) 1998-12-29
DE69620186D1 (de) 2002-05-02
HUP9901448A3 (en) 2002-03-28
EP0840607A1 (en) 1998-05-13
IL122659A0 (en) 1998-08-16
DE69620186T2 (de) 2002-10-31
CA2225175A1 (en) 1997-01-03

Similar Documents

Publication Publication Date Title
SE9502219D0 (sv) Novel medical use
DK0706378T3 (da) Ny farmaceutisk formulering.
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
FR2700117B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
ZA974387B (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases.
SE9402880D0 (sv) New peptide derivatives
SE9600120D0 (sv) Novel medical use
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE155683T1 (de) Arzneimittel zur verhinderung der toleranzentwicklung während der behandlung mit benzodiazepin-rezeptor-bindenden wirkstoffen
ZA9427B (en) Use of riluzole for promoting restoration following radiation